News

Details

Published: 06 September 2016

• portfolio-news

To advance novel RIG-I targeted immuno-oncology therapeutics. The company also announced opening of Cambridge, MA office. 

Details

Published: 10 August 2016

• portfolio-news

Evolva’s collaboration with US Navy to focus on resveratrol-based composites 

Details

Published: 12 July 2016

• portfolio-news

New worldwide, exclusive license agreement provides broad access to Institut Pasteur's virus vector technology – Zika vaccine development progressing with high priority